Status:
COMPLETED
A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
35-65 years
Phase:
PHASE3
Brief Summary
This study was designed to directly assess the effects of vildagliptin on gastric emptying in people with type 2 diabetes.
Eligibility Criteria
Inclusion
- Diagnosed with type 2 diabetes for at least 6 months
- Blood glucose criteria must be met
- BMI in the range 22-40
Exclusion
- History of type 1 diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes
- Use of thiazolidinediones or need for insulin within 3 months prior to screening
- Significant concomitant diseases or complications of diabetes
- High fasting triglycerides as defined by the protocol
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00351507
Start Date
May 1 2005
End Date
February 1 2006
Last Update
May 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905